Drugs / Lacutoclax
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07609862 | May 2026 → Jun 2029 expected | Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma +1 | Guangzhou Lupeng Pharmaceutical Company LTD. | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07609823 | Jul 2026 → Mar 2028 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | Guangzhou Lupeng Pharmaceutical Company LTD. | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lacutoclax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07609823 ↗ |
| Action | Inhibit | “BCL-2 inhibitor” NCT07609823 ↗ |
| Modality | Small molecule | — CHEMBL5314523 ↗ |
| Route | Oral | “oral Lacutoclax tablets” NCT07609823 ↗ |
| Target | BCL2 | “Lacutoclax, an oral selective BCL-2 inhibitor” NCT07609823 ↗ |